Primary progressive


Also found in: Acronyms.

Primary progressive

A pattern of symptoms of multiple sclerosis in which the disease progresses without remission, or with occasional plateaus or slight improvements.
Mentioned in: Multiple Sclerosis
References in periodicals archive ?
Ocrelizumab is the first investigational medicine to significantly reduce disability progression in people with relapsing MS and people with primary progressive MS a form of MS with no approved treatments.
Nothing yet exists which can cure any form of MS, and although beta interferons can help relapsing patients they have no effect against the primary progressive disease.
Its objective is to compare the efficacy and safety of masitinib at 6 mg/kg/day with placebo in the treatment of patients with primary progressive multiple sclerosis or relapse free secondary progressive multiple sclerosis.
The other main types identified are primary progressive MS (PPMS), which affects around 10% of patients at onset, and progressive-relapsing MS (PRMS) which affects up to 5% of patients.
No treatments currently exist that work on slowing disability for those who have Primary Progressive MS and Secondary Progressive MS.
These studies demonstrated the efficacy of Fampridine-PR tablets in improving walking ability in patients with relapsing remitting, secondary progressive, progressive relapsing, and primary progressive MS.
Moreover, cases are segmented into three common sub-types: relapsing-remitting MS, primary progressive MS, and secondary progressive MS.
The idea was inspired after Janet shared in her husband's losing battle with Multiple Sclerosis since he was first diagnosed with primary progressive MS in 1985, shortly after their marriage.
April 29, 2014 /PRNewswire/ -- As a wife and mother of 2 children, Kristen Marr was absolutely devastated when she was diagnosed with Primary Progressive Multiple Sclerosis in 2007.
Patients with primary progressive disease following initial autologous or allogeneic SCT
The unmet medical needs in primary progressive MS (PPMS) and secondary progressive MS (SPMS) segments are opening up significant market expansion opportunities for participants.
Biogen Idecs Rituxan (rituximab) and BioMS MBP-8298 are targeting the prevalent yet largely underserved primary progressive MS (PPMS) and secondary progressive MS (SPMS) indications.

Full browser ?